Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 31 May 2021
Eton Pharmaceuticals receives complete response letter from U.S. FDA for dehydrated alcohol injection
28 May 2021 - Eton Pharmaceuticals today announced that the company has received a complete response letter from the U.S. FDA ...
Posted by Michael Wonder on 31 May 2021
If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it
30 May 2021 - Most visits to the memory centre where I care for individuals living with Alzheimer’s disease end ...
Posted by Michael Wonder on 31 May 2021
State slower to ‘adopt new drugs’ than most of western Europe
31 May 2021 - Medicines regularly not worth approving at asking price. ...
Posted by Michael Wonder on 31 May 2021
FDA grants breakthrough device designation for smart orthopaedic implants
28 May 2021 - Intelligent Implants has announced today that its SmartFuse system has received breakthrough device designation by the ...
Posted by Michael Wonder on 31 May 2021
External reference pricing: the drug pricing reform America needs?
27 May 2021 - External reference pricing, sometimes known as international reference pricing, refers to the practice of informing price negotiations ...
Posted by Michael Wonder on 31 May 2021
White House asks court to dismiss lawsuit over drug imports
31 May 2021 - The Biden administration is urging a federal court to dismiss a lawsuit that could stand in the ...
Posted by Michael Wonder on 31 May 2021
Marketing approval received in Japan for Ninlaro as a maintenance therapy after first-line treatment for multiple myeloma without prior stem cell transplantation
27 May 2021 - Takeda today announced that it has received approval from the Japanese Ministry of Health, Labour and ...
Posted by Michael Wonder on 31 May 2021
Examining the impact of different country processes for appraising rare disease treatments: a case study analysis
31 May 2021 - Conventional appraisal and reimbursement processes are being challenged by the increasing number of rare disease treatments with ...
Posted by Michael Wonder on 31 May 2021
Apotex medicines in New Zealand
31 May 2021 - Apotex has announced that it is leaving the New Zealand market. ...
Posted by Michael Wonder on 30 May 2021
PHARMAC funding will result in health poverty: advocate
30 May 2021 - A Dunedin patient rights campaigner is vowing to fight on in the wake of the Government’s ...
Posted by Michael Wonder on 30 May 2021
Diurnal receives European Commission approval for Efmody
28 May 2021 - Commercial launch anticipated in Q3 2021. ...
Posted by Michael Wonder on 30 May 2021
PBS listed progesterone pessary slashes preterm birth risk
31 May 2021 - A vaginal progesterone pessary is reported to be the first progesterone treatment to be reimbursed via ...
Posted by Michael Wonder on 30 May 2021
US style managed healthcare given green light by Australian consumer watchdog
28 May 2021 - US style managed healthcare has been given the green light by the consumer watchdog, and Australia’s peak ...
Posted by Michael Wonder on 30 May 2021
Calliditas announces submission of marketing authorisation application for Nefecon to the European Medicines Agency
28 May 2021 - Calliditas Therapeutics today announced that the company submitted a marketing authorisation application to the EMA for ...
Posted by Michael Wonder on 29 May 2021
Ipsen confirms U.S. FDA accepts new drug application for palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva
28 May 2021 - New drug application granted priority review status, with a decision anticipated on 30 November 2021. ...